Columnist Sam Kirton has developed some strategies to make the roughly 90-minute commute to his IPF doctor appointments more manageable.

A recent car accident prompted columnist Kylene Henderson and her husband, Donnie, who has PF, to consider how to prepare for emergencies.

The experimental IPF therapy deupirfenidone was granted orphan drug designation by regulatory agencies in the U.S. and the European Union.

Rare Disease Day in February is an important time to raise awareness about a club no one asked to join, writes columnist Sam Kirton.

Targeting ACVRL1, dubbed an 'overlooked' gene by researchers, could potentially lead to new treatments for IPF, a study suggests.

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...

[vc_row][vc_column][vc_column_text]Pulmonary fibrosis (PF) is a respiratory disease that causes the lung tissue to become thick and stiff. Over time, it turns into scar tissue, which is known as ...

Building on positive Phase 2 data, Puretech Health plans to launch a Phase 3 trial in the coming months to further test its experimental oral therapy deupirfenidone (LYT-100) in people with idiopathic ...

Cumberland Pharmaceuticals is launching a Phase 2 clinical trial to assess the safety and efficacy of its investigational therapy, ifetroban, in treating patients with idiopathic pulmonary fibrosis ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Treatment with Ofev (nintedanib) can significantly extend the survival of patients with idiopathic pulmonary fibrosis (IPF), an analysis of pooled data from six clinical trials shows. The analyis, ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due to safety issues. The BEACON-IPF (NCT06097260) ...